DNA minor groove binding agents

Drugs of the Future

Volumn 30, Issue 3, 2005, Pages 301-309

  Damia, Giovanna ^a   Broggini, Massimo ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 8 CARBAMOYLOXYMETHYL 3,9 EPOXY 5 FORMYL 1A,2,3,8,9,9A HEXAHYDRO 9 HYDROXY 7 METHOXY 1H AZIRINO[2,3 C][1]BENZAZOCINE ACETATE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; 4 FORMYL 6,9 DIHYDROXY 14 OXA 1,11 DIAZATETRACYCLO[7.4.1.0 2,7 0 10,12]TETRADECA 2,4,6 TRIEN 8 YLMETHYLCARBAMATE; ACRYLIC ACID DERIVATIVE; ALDOZELESINE; ALPHA BROMOACRYLIC DERIVATIVE; ANTHRACYCLINE DERIVATIVE; ANTHRAMYCIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BENZOIC ACID DERIVATIVE; BENZOIC ACID MUSTARD; BROSTALLICIN; CAMPTOTHECIN; CARZELESINE; CHLORMETHINE DERIVATIVE; CISPLATIN; CONGOCIDINE DERIVATIVE; DISTAMYCIN A; DISTAMYCIN A DERIVATIVE; DNA; DNA MINOR GROOVE BINDING AGENT; DOCETAXEL; DOXORUBICIN; FLUORESCENT DYE; FLUOROURACIL; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HOE 33342; IRINOTECAN; MELPHALAN; METHYLPROAMINE; MICROGONOTROPEN DERIVATIVE; MS 247; PLATINUM DERIVATIVE; PNU 151807; RACHELMYCIN; SIBIROMYCIN; SJG 136; TALLIMUSTINE; TAXANE DERIVATIVE; TOMAYMYCIN; TRABECTEDIN; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; BILIRUBIN BLOOD LEVEL; BONE MARROW TOXICITY; CANCER; CLINICAL TRIAL; COVALENT BOND; DISTRIBUTION VOLUME; DNA MINOR GROOVE; DNA STRUCTURE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SCREENING; DRUG SYNTHESIS; EXCISION REPAIR; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC MALIGNANCY; HUMAN; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; REVIEW; RHABDOMYOLYSIS; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 18844431095     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.03.878168     Document Type: Review

References (64)

1. Reddy, B.S., Sharma, S.K., Lown, J.W. Recent developments in sequence selective minor groove DNA effectors. Curr Med Chem 2001, 8: 475-508.
2. D'Incalci, M. DNA-minor-groove alkylators, a new class of anticancer agents. Ann Oncol 1994, 5: 877-8.
3. Cozzi, P., Mongelli, N. Cytotoxics derived from distamycin A and congeners. Curr Pharm Des 1998, 4: 181-201.
4. Lown, J.W., Krowicki, K., Balzarini, J., Newman, R.A., De Clercq, E. Novel linked antiviral and antitumor agents related to netropsin and distamycin: Synthesis and biological evaluation. J Med Chem 1989, 32: 2368-75.
5. Broggini, M., Erba, E., Ponti, M., Ballinari, D., Geroni, C., Spreafico, F., D'Incalci, M. Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res 1991, 51: 199-204.
6. Broggini, M., Coley, H.M., Mongelli, N., Pesenti, E., Wyatt, M.D., Hartley, J.A., D'Incalci, M. DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res 1995, 23: 81-7.
7. Fontana, M., Lestingi, M., Mondello, C., Braghetti, A., Montecucco, A., Ciarrocchi, G. DNA binding properties of FCE24517, an electrophilic distamycin analogue. Anticancer Drug Des 1992, 7: 131-41.
8. Pezzoni, G., Grandi, M., Biasoli, G. et al. Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A. Br J Cancer 1991, 64: 1047-50.
9. Beran, M., Jeha, S., O'Brien, S. et al. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study. Clin Cancer Res 1997, 3: 2377-84.
10. Sessa, C., Pagani, O., Zurlo, M.G. et al. Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann Oncol 1994, 5: 901-7.
11. Weiss, G.R., Poggesi, I., Rocchetti, M. et al. A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer. Clin Cancer Res 1998, 4: 53-9.
12. Ghielmini, M., Bosshard, G., Capolongo, L. et al. Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer 1997, 75: 878-83.
13. Beria, I., Baraldi, P.G., Cozzi, P. et al. Cytotoxic α- halogenoacrylic derivatives of distamycin A and congeners. J Med Chem 2004, 47: 2611-23.
14. Marchini, S., Ciro, M., Gallinari, F., Geroni, C., Cozzi, P., D'Incalci, M., Broggini, M. α-Bromoacryloyl derivative of distamycin A (PNU 151807): A new non-covalent minor groove DNA binder with antineoplastic activity. Br J Cancer 1999, 80: 991-7.
15. Marchini, S., Ciro, M., Broggini, M. p53-independent caspase-mediated apoptosis in human leukaemic cells is induced by a DNA minor groove binder with antineoplastic activity. Apoptosis 1999, 4: 39-45.
16. Colella, G., Marchini, S., D'Incalci, M., Brown, R., Broggini, M. Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br J Cancer 1999, 80: 338-43.
17. Volpe, D.A., Du, D.L., Zurlo, M.G., Mongelli, N., Murphy, M.J. Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells. Invest New Drugs 1992, 10: 255-61.
18. Marchini, S., Broggini, M., Sessa, C., D'Incalci, M. Development of distamycin-related DNA binding anticancer drugs. Exp Opin Invest Drugs 2001, 10: 1703-14.
19. Geroni, C., Marchini, S., Cozzi, P. et al. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res 2002, 62: 2332-6.
20. Broggini, M., Marchini, S., Fontana, E., Moneta, D., Fowst, C., Geroni, C. Brostallicin: A new concept in minor groove DNA binder development. Anticancer Drugs 2004, 15: 1-6.
21. Cozzi, P. A new class of cytotoxic DNA minor groove binders: α-Halogenoacrylic derivatives of pyrrolecarbamoyl oligomers. Farmaco 2001, 56: 57-65.
22. Fedier, A., Fowst, C., Tursi, J., Geroni, C., Haller, U., Marchini, S., Fink, D. Brostallicin (PNU-166196) - A new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells. Br J Cancer 2003, 89: 1559-65.
23. Sabatino, M.A., Colombo, T., Geroni, C., Marchini, S., Broggini, M. Enhancement of in vivo antitumor activity of classic anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin. Clin Cancer Res 2003, 9: 5402-8.
24. Nishiyama, M., Yamamoto, W., Park, J.-S. et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999, 5: 2620-8.
25. Ten Tije, A.J., Verweij, J., Sparreboom, A. et al. Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer. Clin Cancer Res 2003, 9: 2957-64.
26. Lockhart, A.C., Howard, M., Hande, K.R. et al. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin Cancer Res 2004, 10: 468-75.
27. Pommier, Y., Kohlhagen, G., Bailly, C., Waring, M., Mazumder, A., Kohn, K.W. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996, 35: 13303-9.
28. Moore, B.M. II, Seaman, F.C., Hurley, L.H. NMR-based model of an ecteinascidin 743-DNA adduct. J Am Chem Soc 1997, 119: 5475-6.
29. Erba, E., Cavallaro, E., Damia, G. et al. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring. Oncol Res 2004, 14: 579-87.
30. Bonfanti, M., La Valle, E., Fernandez Sousa Faro, J.M., Faircloth, G., Caretti, G., Mantovani, R., D'Incalci, M. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 1999, 14: 179-86.
31. Friedman, D., Hu, Z., Kolb, E.A., Gorfajn, B., Scotto, K.W. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002, 62: 3377-81.
32. Jin, S., Gorfajn, B., Faircloth, G., Scotto, K.W. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2000, 97: 6775-9.
33. Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G., D'Incalci, M., Mantovani, R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 2000, 97: 6780-4.
34. Martinez, E.J., Corey, E.J., Owa, T. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol 2001, 8: 1151-60.
35. Damia, G., Silvestri, S., Carrassa, L. et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001, 92: 583-8.
36. Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G.T., D'Incalci, M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001, 37: 97-105.
37. Li, W.W., Takahashi, N., Jhanwar, S. et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: Identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001, 7: 2908-11.
38. Hendriks, H.R., Fiebig, H.H., Giavazzi, R., Langdon, S.P., Jimeno, J.M., Faircloth, G.T. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 1999, 10: 1233-40.
39. Valoti, G., Nicoletti, M.I., Pellegrino, A. et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 1998, 4: 1977-83.
40. D'Incalci, M., Colombo, T., Ubezio, P. et al. The combination of Yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003, 39: 1920-6.
41. Takahashi, N., Li, W., Banerjee, D. et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 2002, 62: 6909-15.
42. Meco, D., Colombo, T., Ubezio, P. et al. Effective combination of ET-743 and doxorubicin in sarcoma: Preclinical studies. Cancer Chemother Pharmacol 2003, 52: 131-8.
43. D'Incalci, M., Jimeno, J. Preclinical and clinical results with the natural marine product ET-743. Exp Opin Invest Drugs 2003, 12: 1843-53.
44. Sessa, C., De Braud, F., Perotti, A. et al. Trabectedin (ET-743) for women with ovarian carcinoma after failure of platinum-taxanes. J Clin Oncol 2005, 23: in press.
45. Lee, M., Rhodes, A.L., Wyatt, M.D., Forrow, S., Hartley, J.A. GC base sequence recognition by oligo(imidazolecarboxamide) and C-terminus-modified analogues of distamycin deduced from circular dichroism, proton nuclear magnetic resonance, and methidiumpropylethylenediaminetetraacetate-iron(II) footprinting studies. Biochemistry 1993, 32: 4237-45.
46. Lee, M., Rhodes, A.L., Wyatt, M.D., D'Incalci, M., Forrow, S., Hartley, J.A. In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin. J Med Chem 1993, 36: 863-70.
47. Gregson, S.J., Howard, P.W., Hartley, J.A. et al. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem 2001, 44: 737-48.
48. Hartley, J.A., Spanswick, V.J., Brooks, N. et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 1: Cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 2004, 64: 6693-9.
49. Alley, M.C., Hollingshead, M.G., Pacula-Cox, C.M. et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations. Cancer Res 2004, 64: 6700-6.
50. Pjura, P.E., Grzeskowiak, K., Dickerson, R.E. Binding of Hoechst 33258 to the minor groove of B-DNA. J Mol Biol 1987, 197: 257-71.
51. Zimmer, C., Wahnert, U. Nonintercalating DNA-binding ligands: Specificity of the interaction and their use as tools in biophysical, biochemical and biological investigations of the genetic material. Prog Biophys Mol Biol 1986, 47: 31-112.
52. Martin, R.F., Broadhurst, S., Reum, M.E. et al. In vitro studies with methylproamine: A potent new radioprotector. Cancer Res 2004, 64: 1067-70.
53. Satz, A.L., Bruice, T.C. Recognition of nine base pair sequences in the minor groove of DNA at subpicomolar concentrations by a novel microgonotropen. Bioorg Med Chem 2002, 10: 241-52.
54. White, C.M., Satz, A.L., Bruice, T.C., Beerman, T.A. Inhibition of transcription factor-DNA complexes and gene expression by a microgonotropen. Proc Natl Acad Sci USA 2001, 98: 10590-5.
55. White, C.M., Satz, A.L., Gawron, L.S., Bruice, T.C., Beerman, T.A. Inhibiting transcription factor/DNA complexes using fluorescent microgonotropens (FMGTs). Biochim Biophys Acta 2002, 1574: 100-8.
56. Beckerbauer, L., Tepe, J.J., Cullison, J., Reeves, R., Williams, R.M. FR900482 class of anti-tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo. Chem Biol 2000, 7: 805-12.
57. Beckerbauer, L., Tepe, J.J., Eastman, R.A., Mixter, P.F., Williams, R.M., Reeves, R. Differential effects of FR900432 and FK317 on apoptosis, IL-2 gene expression, and induction of vascular leak syndrome. Chem Biol 2002, 9: 427-41.
58. Matsuba, Y., Edatsugi, H., Mita, I., Matsunaga, A., Nakanishi, O. A novel synthetic DNA minor groove binder, MS-247: Anti-tumor activity and cytotoxic mechanism. Cancer Chemother Pharmacol 2000, 46: 1-9.
59. Yamori, T., Matsunaga, A., Sato, S. et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 1999, 59: 4042-9.
60. Demetri, G.D. ET-743: The US experience in sarcomas of soft tissues. Anticancer Drugs 2002, 13 (Suppl. 1): S7-9.
61. Yovine, A., Riofrio, M., Blay, J.Y. et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004, 22: 890-9.
62. Le Cesne, A., Blay, J.Y., Judson, I. et al. Phase II study of ET-743 in advanced soft-tissue sarcomas: An EORTC soft tissue and bone sarcoma group trial. J Clin Oncol 2005, 23: 576-84.
63. Laverdiere, C., Kolb, E.A., Supko, J.G. et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003, 98: 832-40.
64. Dileo, P., Casali, P.G., Bacci, G. et al. Phase II evaluation of 3-hr infusion ET-743 in patients with recurrent sarcomas. Proc Am Soc Clin Onc 2002, 21: 408a.